Barely Significant
← all excerpts

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS Drugs · 2020 · PMC7773609 · PMID 33108633

1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

nominally significantp < 0.0001actually significant
Given this lack of statistical significance in hierarchical testing, adjusted mean changes from baseline in total lesion volume on T2-weighted (T2W) images at 12 months and 24 months in the siponimod group were considered nominally significant versus placebo (both timepoints p < 0.0001) (Table 1 ), with the adjusted average mean increase from baseline over both timepoints lower in the siponimod than placebo group (183.9 vs 879.2 mm 3 ; nominal p < 0.0001) [ 38 ].

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.